5%+ major-holding disclosures
- 이장한40.15%2026-08-31 · 증감 0.00%p
- KopernikGlobalInvestors,LLC8.38%2026-06-26 · 증감 +1.17%p
- 국민연금공단6.34%2026-07-01 · 증감 -1.01%p
₩65,700+0.77%
2026-10-06 closeChong Kun Dang Pharmaceutical's company information is shown as of 2026-10-06. It is a security listed on KOSPI, ticker 185750. There are 14 published related companies.
About this company
Chong Kun Dang Pharmaceutical last closed at ₩65,700 (+0.77%) on 2026-10-06. Signals today: VCP, MACD bullish cross. Listed on KOSPI.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F is quarterly and may be filed up to 45 days later.
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 종근당홀딩스KRA001630 →
Shared holders: 이장한
- 피에이치에이KRA043370 →
Shared holders: KopernikGlobalInvestors,LLC
- LX홀딩스KRA383800 →
Shared holders: KopernikGlobalInvestors,LLC
Suppliers, competitors and related stocks
- 삼성바이오에피스Competitor
바이오시밀러 및 항체의약품 경쟁
- 셀트리온Competitor
바이오시밀러 중심의 국내외 경쟁사
- 한미약품Competitor
처방의약품·신약개발 분야 경쟁
- 유한양행Competitor
국내 대형 제약사로 전문의약품 경쟁
- 대웅제약Competitor
국내 전문의약품 및 신약 경쟁사
- GC녹십자Competitor
백신·혈액제제·전문의약품 경쟁
- 보령Competitor
호흡기·순환기 등 전문의약품 경쟁
- 아스트라제네카Supplier
글로벌 오픈이노베이션·기술이전 협력의 대표적 해외 파트너
- 화이자Competitor
글로벌 제약사로 국내 처방의약품 시장에서 경쟁 기준점
- 노바티스Competitor
글로벌 혁신신약 및 전문의약품 경쟁사
- 사노피Competitor
백신·당뇨·희귀질환 등 글로벌 제약 경쟁사
- 노보 노디스크Competitor
대사질환·당뇨 치료제 분야 글로벌 경쟁사
- 종근당홀딩스Related theme
지배구조상 그룹 핵심 연결고리
- 종근당바이오Related theme
미생물 발효·원료의약품 등 그룹 내 관련 사업
Major stocks in the same sector
2026-10-06 dataset
Disclosed suppliers
2026-03-18 dataset
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ KRW 0.1B(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Quantus Signal · live data · not investment advice · Privacy Policy